Details of the Drug Reposition

General Information of This Drug (ID: DM9Z4N5)

Drug Name
Zilucoplan   DM9Z4N5
Synonyms RA101495
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Generalized myasthenia gravis DISQOYF5 8C60 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myasthenia gravis DISELRCI 8C6Y Phase 3 [2]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Paroxysmal nocturnal haemoglobinuria DISBHMYH 3A21.0 Phase 2 [3]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216834
2 ClinicalTrials.gov (NCT04225871) Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT). U.S. National Institutes of Health.
3 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.